Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) Short Interest Update

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) was the target of a significant decline in short interest in October. As of October 31st, there was short interest totalling 54,700 shares, a decline of 31.5% from the October 15th total of 79,900 shares. Approximately 4.1% of the shares of the company are short sold. Based on an average daily volume of 181,100 shares, the days-to-cover ratio is currently 0.3 days.

Sonoma Pharmaceuticals Trading Down 0.8 %

SNOA traded down $0.02 on Friday, reaching $2.56. The company had a trading volume of 15,310 shares, compared to its average volume of 159,561. The company has a market capitalization of $3.43 million, a P/E ratio of -0.51 and a beta of 1.38. The company has a fifty day moving average of $3.08 and a 200-day moving average of $1.35. Sonoma Pharmaceuticals has a one year low of $2.52 and a one year high of $9.37.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Sonoma Pharmaceuticals stock. Ground Swell Capital LLC purchased a new position in Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund purchased 10,400 shares of the company’s stock, valued at approximately $32,000. Ground Swell Capital LLC owned about 1.08% of Sonoma Pharmaceuticals as of its most recent filing with the Securities & Exchange Commission. 1.95% of the stock is currently owned by institutional investors.

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc, develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis.